Advertisement

Clinically-indicated ibrutinib dose interruptions and reductions do not compromise long-term outcomes in CLL

Inhye E Ahn, Neil Basumallik, Xin Tian, Susan J. Soto and Adrian Wiestner
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.